Marshall Medical Center in Placerville, CA, and UC Davis Health have entered an affiliation for cancer services that allows Marshall patients access to the UC Davis Comprehensive Cancer Center through the UC Davis Health Cancer Care Network.
Black women experienced higher rates of breast cancer-related lymphedema than white women, and Black race was the strongest predictor of lymphedema development, according to results presented at the San Antonio Breast Cancer Symposium.
Every cancer center seeking to obtain (or keep) an NCI designation will soon have to present a plan for increasing the diversity of their faculty and workforce.
DEI Network founders: Let’s work together to increase diversity across all cancer centers in America
Christopher Li and Wendy Law, both of Fred Hutchinson Cancer Research Center, have a message for leaders of DEI programs in oncology.
Emergent public-private partnerships (PPPs) have risen to the occasion to streamline and coordinate severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. With these monumental efforts have come important public discussions about equitable access and representation in clinical trials (CTs).
Bridget Oppong was named deputy director of the Center for Cancer Health Equity at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).
FDA watchers and clinical trialists in oncology may want to pay close attention to the agency’s latest plans to increase representation of traditionally marginalized populations in drug development.
There’s a cultural perception in drug development that enrolling a diverse, heterogeneous patient cohort can be “risky” for detecting drug effects—a perception that needs to go away, said Lola Fashoyin-Aje, associate director of the Science & Policy Program to Address Disparities at the FDA’s Oncology Center of Excellence and a deputy division director in the agency’s Office of Oncologic Diseases.
Drug manufacturers and researchers have a moral obligation to design clinical trials that adequately represent the target population for the investigational agent—and these medical products need to be safe and effective for everyone, leading clinical trial experts in oncology say.
Few people can say they have contributed more to our field than Dr. Walter Lawrence, Jr., and we are so deeply saddened by his passing Nov. 9 at age 96.
